Cubist Systematic Strategies’s Aerie Pharmaceuticals AERI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-32,335
Closed -$489K 4957
2022
Q3
$489K Buy
32,335
+5,313
+20% +$61.8K ﹤0.01% 3178
2022
Q2
$203K Sell
27,022
-82,588
-75% -$582K ﹤0.01% 3692
2022
Q1
$997K Sell
109,610
-346,417
-76% -$2.67M 0.01% 2026
2021
Q4
$3.2M Buy
+456,027
New +$4.77M 0.03% 973
2021
Q2
Sell
-72,413
Closed -$1.29M 3189
2021
Q1
$1.29M Sell
72,413
-20,505
-22% -$354K 0.02% 1362
2020
Q4
$1.25M Sell
92,918
-32,977
-26% -$398K 0.02% 1226
2020
Q3
$1.48M Sell
125,895
-17,832
-12% -$217K 0.02% 1092
2020
Q2
$2.12M Buy
143,727
+44,420
+45% +$657K 0.04% 753
2020
Q1
$1.34M Sell
99,307
-28,183
-22% -$535K 0.04% 657
2019
Q4
$3.08M Buy
127,490
+79,464
+165% +$1.65M 0.06% 517
2019
Q3
$923K Sell
48,026
-708
-1% -$16.2K 0.02% 1005
2019
Q2
$1.44M Buy
+48,734
New +$1.88M 0.03% 844
2019
Q1
Sell
-16,542
Closed -$597K 2473
2018
Q4
$597K Sell
16,542
-6,110
-27% -$287K 0.03% 849
2018
Q3
$1.39M Buy
+22,652
New +$1.46M 0.08% 332
2017
Q4
Sell
-8,106
Closed -$394K 2156
2017
Q3
$394K Buy
+8,106
New +$442K 0.02% 977
2017
Q2
Sell
-13,300
Closed -$603K 1936
2017
Q1
$603K Buy
+13,300
New +$593K 0.04% 557
2016
Q1
Sell
-1,299
Closed -$32K 1901
2015
Q4
$32K Buy
+1,299
New +$30.3K ﹤0.01% 1646
2015
Q1
Sell
-1,300
Closed -$38K 2133
2014
Q4
$38K Buy
+1,300
New +$33K ﹤0.01% 1794

Cubist Systematic Strategies's AERI Position: Q4 2022 in Review

Cubist Systematic Strategies sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 32,335 shares — an estimated $489K sold.

Cubist Systematic Strategies first reported a position in AERI in Q4 2014 and held it in 18 quarters. The position peaked at $3.2M in Q4 2021. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.

  • Cubist Systematic Strategies reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Cubist Systematic Strategies sold 32,335 Aerie Pharmaceuticals shares in Q4 2022, an estimated $489K.
  • Cubist Systematic Strategies first reported a position in Aerie Pharmaceuticals in Q4 2014 and held it in 18 quarters.
  • Cubist Systematic Strategies's Aerie Pharmaceuticals position peaked at $3.2M in Q4 2021.
  • 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.

Based on Cubist Systematic Strategies's 13F filing for Q4 2022, filed 14 Feb 2023.